Haverford Trust Co Purchases New Position in Globe Life Inc. $GL

Haverford Trust Co purchased a new position in Globe Life Inc. (NYSE:GL) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 4,758 shares of the company’s stock, valued at approximately $850,000.

A number of other hedge funds also recently bought and sold shares of the business. CYBER HORNET ETFs LLC acquired a new stake in Globe Life in the 2nd quarter valued at $28,000. Hilton Head Capital Partners LLC purchased a new stake in Globe Life during the 4th quarter worth approximately $30,000. MUFG Securities EMEA plc purchased a new stake in Globe Life during the 2nd quarter worth approximately $31,000. Torren Management LLC acquired a new position in shares of Globe Life during the fourth quarter valued at approximately $37,000. Finally, Johnson Financial Group Inc. acquired a new position in shares of Globe Life during the second quarter valued at approximately $39,000. Hedge funds and other institutional investors own 81.61% of the company’s stock.

Globe Life Stock Up 0.3%

GL stock opened at $171.07 on Friday. The company has a market cap of $13.15 billion, a price-to-earnings ratio of 11.36 and a beta of 0.48. The company has a current ratio of 0.07, a quick ratio of 0.07 and a debt-to-equity ratio of 0.43. Globe Life Inc. has a 12 month low of $127.85 and a 12 month high of $191.55. The firm has a 50-day moving average of $178.36 and a two-hundred day moving average of $158.52.

Globe Life (NYSE:GL) last released its earnings results on Wednesday, July 22nd. The company reported $3.61 earnings per share for the quarter, missing analysts’ consensus estimates of $3.67 by ($0.06). The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.59 billion. Globe Life had a return on equity of 20.52% and a net margin of 19.58%.The company’s revenue for the quarter was up 8.0% compared to the same quarter last year. During the same period last year, the business earned $3.05 earnings per share. Globe Life has set its FY 2026 guidance at 15.550-15.950 EPS. As a group, analysts forecast that Globe Life Inc. will post 15.71 earnings per share for the current fiscal year.

Globe Life announced that its Board of Directors has initiated a share buyback plan on Monday, August 10th that permits the company to repurchase $2.50 billion in shares. This repurchase authorization permits the company to buy up to 17.7% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Globe Life Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Monday, October 5th will be issued a $0.33 dividend. This represents a $1.32 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Monday, October 5th. Globe Life’s dividend payout ratio (DPR) is currently 8.76%.

Insider Activity

In other Globe Life news, Director Cheryl Alston sold 8,258 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $179.24, for a total value of $1,480,163.92. Following the completion of the sale, the director directly owned 16,621 shares in the company, valued at $2,979,148.04. This represents a 33.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James Matthew Darden sold 50,000 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $182.43, for a total value of $9,121,500.00. Following the completion of the sale, the chief executive officer directly owned 58,451 shares of the company’s stock, valued at $10,663,215.93. This trade represents a 46.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 151,908 shares of company stock valued at $27,239,981 in the last 90 days. 2.11% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on GL shares. Keefe, Bruyette & Woods lowered their price target on Globe Life from $192.00 to $190.00 and set an “outperform” rating on the stock in a research note on Friday, July 24th. Wells Fargo & Company increased their price objective on Globe Life from $172.00 to $193.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Weiss Ratings lowered Globe Life from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, July 20th. TD Cowen raised their price objective on Globe Life from $215.00 to $225.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Finally, Jefferies Financial Group lifted their target price on shares of Globe Life from $147.00 to $166.00 and gave the stock a “hold” rating in a research note on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $191.67.

About Globe Life

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.